IP Library › Granted Patent US 12,458,642
Granted Patent B2
US 12,458,642 · App. 17/350,726 · Granted Nov 4, 2025

Metalloenzyme inhibitor compounds

Inventors: Steven Sparks (Apex, NC); Christopher M. Yates (Raleigh, NC); Sammy R. Shaver (Chapel Hill, NC); William J. Hoekstra (Durham, NC)
Assignee: Corxel Pharmaceuticals Hong Kong Limited
A61K31/501A61K31/4184A61K31/4188A61K31/437C07D401/14C07D403/04C07D403/14C07D405/14C07D417/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,642
App. No.
17/350,726
Granted
Nov 4, 2025
Kind
B2
Abstract

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes. In some embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, a provided method is a method of alleviating or abating a disorder or disease associated with aldosterone synthase (CYP11B2) or ameliorating a symptom thereof.

Claims (151)

1 . A method of alleviating or abating a disorder or disease or ameliorating a symptom thereof, comprising administering to a subject an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein

A is N;

W is N or CR 6 ;

X is N or CR 6 ;

Y is N or CR 6 ;

Z is N or CR 6 ;

provided that no more than two of W, X, Y, and Z are N;

R 1 is halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, NR a R b , NHSO 2 R c , CH 2 NR a R b , CR e R f NHSO 2 R d , OR f , SR f , CO 2 R e , COR f , S(O)R d , S(O) 2 R d , CH 2 OR f , or CR e R f OH, wherein any R 1 can be optionally substituted with 1-3 independent substituents R 7 ;

R 2 is hydrogen, halogen, cyano, alkyl, or haloalkyl;

or R 1 and R 2 together with the atoms to which they are attached form an aryl, or cycloalkyl ring;

R 3 is hydrogen, halogen, cyano, acyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, cycloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, NR a R b , NHSO 2 R c , CH 2 NR a R b , CH 2 NHSO 2 R d , CO 2 R e , COR f , CH 2 OR f , or CR e R f OH;

R 4 is cycloalkyl;

each occurrence of R 6 is, independently, hydrogen, halogen, cyano, haloalkyl, alkyl, cycloalkyl, alkoxy, haloalkyl, OR f , or carboxyl;

each occurrence of R 7 is, independently, halogen, alkyl, alkoxy, haloalkyl, carboxyl, cycloalkyl, aryl, aryl substituted with 1-3 independent halogen, —(CH 2 )nC(O)NR g R h , —S(O) 2 R i , —CO 2 R j , or NR g R h ,

each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

each occurrence of R a , R b , R c , R d , R e , and R f is, independently, hydrogen, acyl, alkoxyalkyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C(O)OC 1-6 alkyl, C(O)C 1-6 alkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom; or R a and R b together with the atoms to which they are attached form a heterocycloalkyl ring; or R e and R f together with the atoms to which they are attached form a cycloalkyl ring; and

each occurrence of R g , R h , R i , and R j is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C(O)OC 1-6 alkyl, C(O)C 1-6 alkyl, or R g and R h together with the atoms to which they are attached form a heterocycloalkyl ring,

wherein the disorder or disease is hypertension, resistant hypertension, primary or secondary hyperaldosteronism, heart failure, or obstructive sleep apnea.

2 . The method of claim 1 , wherein the disease or disorder is primary or secondary hyperaldosteronism.

3 . The method of claim 1 , wherein the disease or disorder is hypertension.

4 . The method of claim 3 , wherein the hypertension is resistant hypertension.

5 . The method of claim 1 , wherein the disease or disorder is obstructive sleep apnea.

6 . The method of claim 1 , wherein the disease or disorder is congestive heart failure.

7 . The method of claim 1 , wherein R 1 is hydrogen, halogen, alkyl, alkenyl, haloalkyl, alkoxy, haloalkoxy, cycloalkoxy, aryl, NR a R b , CR e R f NHSO 2 R d , SR f , or CR e R f OH; or R 1 and R 2 together with the atoms to which they are attached form an aryl or cycloalkyl ring.

8 . The method of claim 7 , wherein:

R 1 is hydrogen, halogen, alkyl, haloalkyl, CR e R f NHSO 2 R d , SR f , or NR a R b , and

R a , R b , R d , R e , and R f are, independently, hydrogen, alkyl, or haloalkyl.

9 . The method of claim 1 , wherein R 1 is haloalkyl.

10 . The method of claim 1 , wherein W, X, Y, and Z are each independently CR 6 .

11 . The method of claim 1 , wherein R 2 is hydrogen or alkyl.

12 . The method of claim 1 , wherein each R 6 is, independently, hydrogen, halogen, or cyano.

13 . The method of claim 1 , wherein the compound is of Formula I-a:

or a pharmaceutically acceptable salt thereof.

14 . The method of claim 1 , wherein the compound is of Formula I-b:

or a pharmaceutically acceptable salt thereof.

15 . The method of claim 1 , wherein the compound is of Formula I-c:

or a pharmaceutically acceptable salt thereof.

16 . The method of claim 1 , wherein the compound is of Formula I-d:

or a pharmaceutically acceptable salt thereof.

17 . The method of claim 1 , wherein the compound is of Formula I-e:

or a pharmaceutically acceptable salt thereof.

18 . The method of claim 1 , wherein the compound is of Formula I-f:

or a pharmaceutically acceptable salt thereof.

19 . The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:

20 . The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:

5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carbonitrile (2);

2-(6-chloropyridazin-4-yl)-1-cyclopropyl-6-fluoro-1H-benzo[d]imidazole (3);

1-cyclopropyl-6-fluoro-2-(6-vinylpyridazin-4-yl)-1H-benzo[d]imidazole (4);

1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-6-fluoro-1H-benzo[d]imidazole (6);

1-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (7);

N-((5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl) propionamide (8);

ethyl ((5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl)carbamate (9);

4-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)morpholine (10);

2-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl) propan-2-ol (12);

5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-(tetrahydro-2H-pyran-4-yl)pyridazin-3-amine (13);

4-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)cinnoline (14);

1-cyclopropyl-6-fluoro-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (15);

N-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethanesulfonamide (16);

2-(4-(5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl) piperazin-1-yl)-N-isopropylacetamide (18);

1-cyclopropyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (19);

5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-N-methylpyridazin-3-amine (21);

2-(6-chloropyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole (22);

1-cyclopropyl-5,6-difluoro-2-(6-methoxypyridazin-4-yl)-1H-benzo[d]imidazole (23);

1-cyclopropyl-5,6-difluoro-2-(6-isopropoxypyridazin-4-yl)-1H-benzo[d]imidazole (24);

5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-N,N-dimethylpyridazin-3-amine (25);

1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1H-benzo[d]imidazole (27);

5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-N-(2-methoxyethyl)pyridazin-3-amine (28);

1-cyclopropyl-2-(6-methoxypyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (29);

N-((5-(1-cyclopropyl-6-fluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl)ethanesulfonamide (31);

5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-N-(2,2,2-trifluoroethyl)pyridazin-3-amine (32);

1-cyclopropyl-2-(6-ethylpyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (33);

2-(6-chloropyridazin-4-yl)-1-cyclopropyl-1H-benzo[d]imidazole-6-carbonitrile (34);

1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (35);

1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (42);

2-(6-cyclobutoxypyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole (43);

1-cyclopropyl-2-(6-(4,4-difluoropiperidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (44);

5-chloro-3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3H-imidazo[4,5-b]pyridine (45);

1-cyclopropyl-2-(6-(3,3-difluoropyrrolidin-1-yl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (46);

1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)-2,2,2-trifluoroethan-1-ol (47);

1-cyclopropyl-5,6-difluoro-2-(6-(4-fluorophenyl)pyridazin-4-yl)-1H-benzo[d]imidazole (49);

1-cyclopropyl-5,6-difluoro-2-(6-((4-fluorophenyl) ethynyl)pyridazin-4-yl)-1H-benzo[d]imidazole (50);

1-cyclopropyl-5,6-difluoro-2-(6-isopropylpyridazin-4-yl)-1H-benzo[d]imidazole (51);

N-((5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl) ethanesulfonamide (52);

1-cyclopropyl-5,6-difluoro-2-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyridazin-4-yl)-1H-benzo[d]imidazole (53);

3-cyclopropyl-2-(6-methylpyridazin-4-yl)-3H-imidazo[4,5-b]pyridine-5-carbonitrile (54);

1-cyclopropyl-5,6-difluoro-2-(pyridazin-4-yl)-1H-benzo[d]imidazole (55);

1-cyclopropyl-2-(6-(2,2-difluoropropoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (57);

1-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (59);

2-(6-chloropyridazin-4-yl)-3-cyclopropyl-5-methoxy-3H-imidazo[4,5-b]pyridine (60);

1-cyclopropyl-5,6-difluoro-2-(6-(4-fluoro-2-methylphenyl)pyridazin-4-yl)-1H-benzo[d]imidazole (61);

1-cyclopropyl-2-(6-(2,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (62);

1-cyclopropyl-2-(6-(3,4-difluorophenyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (63);

1-(5-(1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl) ethan-1-one (64);

1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (66);

1-cyclopropyl-2-(6-(1,1-difluoroethyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (70);

1-cyclopropyl-5,6-difluoro-2-(6-(2,2,2-trifluoroethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (71);

5-Chloro-3-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3H-imidazo[4,5-b]pyridine (73);

1-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (75);

3-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-3H-imidazo[4,5-b]pyridine-5-carbonitrile (76);

N-((5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl) methane sulfonamide (77);

N-((5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)methyl) propane-2-sulfonamide (79);

1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfonyl)pyridazin-4-yl)-1H-benzo[d]imidazole (80);

1-Cyclopropyl-2-(6-(ethylsulfonyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (81);

1-Cyclopropyl-5,6-difluoro-2-(6-(methylsulfinyl)pyridazin-4-yl)-1H-benzo[d]imidazole (82);

1-cyclopropyl-2-(6-(ethylsulfinyl)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (83);

5-Chloro-3-cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3H-imidazo[4,5-b]pyridine (84);

1-Cyclopropyl-5,6-difluoro-2-(6-(trifluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (85);

1-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (86);

3-Cyclopropyl-2-(6-cyclopropylpyridazin-4-yl)-3H-imidazo[4,5-b]pyridine-5-carbonitrile (87);

3-Cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3H-imidazo[4,5-b]pyridine-5-carbonitrile (89);

1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazole (90);

N-(1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethyl) methanesulfonamide (91);

1-Cyclopropyl-5,6-difluoro-2-(6-(fluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (92);

1-Cyclopropyl-2-(5,6-dimethylpyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (93);

(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl) methanol (94);

5-Chloro-3-cyclopropyl-2-(6-(trifluoromethyl)pyridazin-4-yl)-3H-imidazo[4,5-b]pyridine (95);

N-(1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl)ethyl) ethanesulfonamide (96);

2-(6-Butylpyridazin-4-yl)-1-cyclopropyl-5,6-difluoro-1H-benzo[d]imidazole (97);

1-Cyclopropyl-6-methyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (98);

1-Cyclopropyl-2-(3,6-dimethylpyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (100);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6,7-difluoro-1H-benzo[d]imidazole (101);

5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-thiol (102);

4-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-5,6,7,8-tetrahydrocinnoline (106);

1-Cyclopropyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole-5-carbonitrile (Ex. 107);

1-Cyclobutyl-5,6-difluoro-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (108);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazol-6-ol (109);

5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazine-3-carboxylic acid (110);

1-Cyclopropyl-7-fluoro-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (111);

5-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (112);

4-Chloro-1-cyclopropyl-2-(6-methylpyridazin-4-yl)-1H-benzo[d]imidazole (113);

1-Cyclopropyl-5,6-difluoro-2-(6-(methoxymethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (114);

Methyl 5-(6-cyano-1-cyclopropyl-1H-benzo[d]imidazol-2-yl)pyridazine-3-carboxylate (115);

5-(6-Cyano-1-cyclopropyl-1H-benzo[d]imidazol-2-yl)pyridazine-3-carboxylic acid (116);

1-Cyclopropyl-2-(6-(cyclopropylmethoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (117);

1-Cyclopropyl-2-(6-(2,2,2-trifluoroethoxy)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (118);

6-Chloro-1-cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1H-benzo[d]imidazole (119);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-5-fluoro-1H-benzo[d]imidazole-6-carbonitrile (120);

4-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)-6,7-dihydro-5H-cyclopenta[c]pyridazine (121);

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-6-fluoro-1H-benzo[d]imidazole (122);

1-Cyclopropyl-5,6-difluoro-2-(6-(methylthio)pyridazin-4-yl)-1H-benzo[d]imidazole (123);

1-Cyclopropyl-5,6-difluoro-2-(6-(isopropylthio)pyridazin-4-yl)-1H-benzo[d]imidazole (124);

1-Cyclopropyl-2-(6-((difluoromethyl)thio)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (125);

5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-ol (126);

1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-5,6-difluoro-1H-benzo[d]imidazole (127);

1-(5-(1-Cyclopropyl-5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridazin-3-yl) ethan-1-ol (128);

1-Cyclopropyl-5,6-difluoro-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (129);

1-Cyclopropyl-5,6-difluoro-2-(6-((trifluoromethyl)thio)pyridazin-4-yl)-1H-benzo[d]imidazole (130)

1-Cyclopropyl-2-(6-(difluoromethyl)pyridazin-4-yl)-1H-benzo[d]imidazole (131);

1-Cyclopropyl-2-(6-(difluoromethoxy)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (133);

1-Cyclopropyl-2-(6-(1-fluoroethyl)pyridazin-4-yl)-1H-benzo[d]imidazole-6-carbonitrile (136).

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2026
From: CORXEL PHARMACEUTICALS LIMITED
To: CORXEL PHARMACEUTICALS, INC.
Reel/Frame 073958/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2026
From: CORXEL PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS LIMITED
Reel/Frame 073958/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: SPARKS, STEVEN; YATES, CHRISTOPHER M.; SHAVER, SAMMY R.; HOEKSTRA, WILLIAM J.
To: VIAMET PHARMACEUTICALS (NC), INC.
Reel/Frame 072436/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: VIAMET PHARMACEUTICALS (NC), INC.
To: VIAMET PHARMACEUTICALS (BERMUDA), LTD.
Reel/Frame 072436/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: SELENITY THERAPEUTICS (BERMUDA), LTD.
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 072436/0232 →
CHANGE OF NAME Recorded Oct 1, 2025
From: VIAMET PHARMACEUTICALS (BERMUDA), LTD.
To: SELENITY THERAPEUTICS (BERMUDA), LTD.
Reel/Frame 072988/0090 →
CHANGE OF NAME Recorded Mar 14, 2025
From: JI XING PHARMACEUTICALS HONG KONG LIMITED
To: CORXEL PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 070523/0516 →
CORRECTION OF ERROR IN ASSIGNEE ADDRESS AS LISTED IN COVER SHEET PREVIOUSLY RECORDED AT REEL/FRAME 062691/0373 Recorded Jun 6, 2023
From: PHASEBIO PHARMACEUTICALS, INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 063873/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2023
From: PHASEBIO PHARMACEUTICALS, INC.
To: JI XING PHARMACEUTICALS HONG KONG LIMITED
Reel/Frame 062691/0373 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: PHASEBIO PHARMACEUTICALS, INC.
Reel/Frame 062376/0850 →
SECURITY INTEREST Recorded Oct 31, 2022
From: PHASEBIO PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 061601/0001 →
SECURITY INTEREST Recorded Oct 10, 2022
From: PHASEBIO PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 061367/0674 →
Continuity (4)
Continuation 16124846 · Sep 7, 2018
Continuation 15857950 · Dec 29, 2017
Provisional Application 62440181 · Dec 29, 2016
Related Publication 20210322409A1 · Oct 21, 2021
References Cited (180)
US 4309551A · Schoenberger et al. · 1982 [cited by applicant]
US 4738851A · Schoenwald et al. · 1988 [cited by applicant]
US 4882150A · Kaufman · 1989 [cited by applicant]
US 4921475A · Sibalis · 1990 [cited by applicant]
US 5008110A · Benecke et al. · 1991 [cited by applicant]
US 5077033A · Viegas et al. · 1991 [cited by applicant]
US 5087240A · Sibalis · 1992 [cited by applicant]
US 5088977A · Sibalis · 1992 [cited by applicant]
US 5106863A · Hajos et al. · 1992 [cited by applicant]
US 5163899A · Sibalis · 1992 [cited by applicant]
US 5164189A · Farhadieh et al. · 1992 [cited by applicant]
US 5254346A · Tucker et al. · 1993 [cited by applicant]
US 5290561A · Farhadieh et al. · 1994 [cited by applicant]
US 5336168A · Sibalis · 1994 [cited by applicant]
US 5352456A · Fallon et al. · 1994 [cited by applicant]
US 5403841A · Lang et al. · 1995 [cited by applicant]
US 5407713A · Wilfong et al. · 1995 [cited by applicant]
US 5521222A · Ali et al. · 1996 [cited by applicant]
US 5698219A · Valdivia et al. · 1997 [cited by applicant]
US 5776445A · Cohen et al. · 1998 [cited by applicant]
US 5800807A · Hu et al. · 1998 [cited by applicant]
US 6056950A · Saettone et al. · 2000 [cited by applicant]
US 6197934B1 · DeVore et al. · 2001 [cited by applicant]
US 6261547B1 · Bawa et al. · 2001 [cited by applicant]
US 7169801B2 · Bressi et al. · 2007 [cited by applicant]
US 7314936B2 · Daun et al. · 2008 [cited by applicant]
US 7855202B2 · Vidal Juan et al. · 2010 [cited by applicant]
US 8188131B2 · Edge et al. · 2012 [cited by applicant]
US 8188282B2 · Alonso et al. · 2012 [cited by applicant]
US 8629147B2 · Anikin et al. · 2014 [cited by applicant]
US 8735586B2 · Alonso et al. · 2014 [cited by applicant]
US 9382226B2 · Hoyt · 2016 [cited by examiner]
US 10085984B2 · Sparks et al. · 2018 [cited by applicant]
US 10538511B2 · Sparks et al. · 2020 [cited by applicant]
US 11040034B2 · Sparks et al. · 2021 [cited by applicant]
US 11136309B2 · Sparks et al. · 2021 [cited by applicant]
US 20080027044A1 · Lewis et al. · 2008 [cited by applicant]
US 20080255085A1 · Arvidsson et al. · 2008 [cited by applicant]
US 20080312175A1 · Yao et al. · 2008 [cited by applicant]
US 20090010566A1 · Meijers · 2009 [cited by applicant]
US 20090105266A1 · Glatthar et al. · 2009 [cited by applicant]
US 20110236307A1 · Jones · 2011 [cited by applicant]
US 20150088111A1 · Brennan · 2015 [cited by examiner]
US 20160074367A1 · Rogers et al. · 2016 [cited by applicant]
US 20160108026A1 · Hornberger · 2016 [cited by examiner]
US 20180185362A1 · Sparks et al. · 2018 [cited by applicant]
US 20180186773A1 · Sparks et al. · 2018 [cited by applicant]
US 20190008861A1 · Sparks et al. · 2019 [cited by applicant]
US 20200392112A1 · Sparks et al. · 2020 [cited by applicant]
US 20220009907A1 · Sparks et al. · 2022 [cited by applicant]
US 20220081420A1 · Sparks et al. · 2022 [cited by applicant]
CN 101321753A · 2008 [cited by applicant]
CN 102076665A · 2011 [cited by applicant]
CN 103626783A · 2014 [cited by applicant]
EP 1604988A1 · 2005 [cited by applicant]
EP 2624832A1 · 2013 [cited by applicant]
EP 2624832B1 · 2017 [cited by applicant]
JP 2011525894A · 2011 [cited by applicant]
RU 2380368C2 · 2010 [cited by applicant]
WO WO0078761A1 · 2000 [cited by applicant]
WO WO2003035065A1 · 2003 [cited by applicant]
WO WO03035065A1 · 2003 [cited by applicant]
WO WO2005111018A1 · 2005 [cited by applicant]
WO WO2006080821A1 · 2006 [cited by applicant]
WO WO2008009348A1 · 2008 [cited by applicant]
WO WO2009000413A1 · 2008 [cited by applicant]
WO WO2009045385A1 · 2009 [cited by applicant]
WO WO2009100438A2 · 2009 [cited by applicant]
WO WO2009156462A2 · 2009 [cited by applicant]
WO WO2010130796A1 · 2010 [cited by applicant]
WO WO2011061168A1 · 2011 [cited by applicant]
WO WO2012012478A1 · 2012 [cited by applicant]
WO WO2012177852A1 · 2012 [cited by applicant]
WO WO2013034047A1 · 2013 [cited by applicant]
WO WO2015163427A1 · 2015 [cited by applicant]
WO WO2015188369A1 · 2015 [cited by applicant]
WO WO2018118781A1 · 2018 [cited by applicant]
WO WO2018125800A2 · 2018 [cited by applicant]
WO WO2018125799A2 · 2018 [cited by applicant]
WO WO2020146532A1 · 2020 [cited by applicant]
Guo, C., Zhang, G., Wu, C., Lei, Y., Wang, Y. and Yang, J. Eur. J. Med. Chem. 2024, 274, 116521. [cited by examiner]
Papillion, J. P. N. et. al. J. Med. Chem. 2015, 58, 9382-9394. [cited by examiner]
Guo, C., Zhang, G., Wu, C., Lei, Y., Wang, Y. and Yang, J. Eur. J. Med. Chem. 2024, 274, 116521 (Year: 2024). [cited by examiner]
Papillion, J. P. N. et. al. J. Med. Chem. 2015, 58, 9382-9394 (Year: 2015). [cited by examiner]
Calhoun, D. A. et. al. Circulation, 2011, 124(18), 1945-1955 (Year: 2011). [cited by examiner]
Bernhardt, R., The potential of targeting CYP11B, Expert Opinion on Therapeutic Targets, 43 pages (2016). [cited by applicant]
Brown, N. J., Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis, Nat. Rev. Nephrol., 9(8):459-469 (2013). [cited by applicant]
Del Vecchio, L. et al., Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade, Nature Clinical Practicenephrology, 3(1): 42-49 (2007). [cited by applicant]
Gomez-Sanchez, C. E. et al., Immunohistochemistry of the Adrenal In Primary Aldosteronism, Curr Opin Endocrinol Diabetes Obes., 25(3):242-248 (2016). [cited by applicant]
Gromotowicz-Poplawska, A. et al., New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?, Experimental Biology and Medicine, 241:1888-1899 (2016). [cited by applicant]
Haznedaroglu, I. C. et al., Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies, European Review for Medical and Pharmacological Sciences, 20: 4089-4111 (2016). [cited by applicant]
He, B. J. et al., Aldosterone and cardiovascular disease: the heart of the matter, Trends Endocrinol Metab., 24(1):21-30 (2013). [cited by applicant]
Hu, Q. et al., Selective Dual Inhibitors of CYP119 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer, Journal of Medicinal Chemistry, pp. A-J, (2012). [cited by applicant]
Kawarazaki, W. et al., The Role of Aldosterone in Obesity-Related Hypertension, American Journal of Hypertension, 29(4): 415-423 (2016). [cited by applicant]
Lehmann, T. et al., The molecular basis of adrenocortical cancer, Cancer Genetics, 205:1331-1337 (2012). [cited by applicant]
Nakamura, Y. et al., Expression of CYP11B2 in Aldosterone-Producing Adrenocortical Adenoma: Regulatory Mechanisms and Clinical Significance, Tohoku J. Exp. Med., 240(3):183-190 (2016). [cited by applicant]
Papillon, J. P. et al., Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects, Journal of Medic… [cited by applicant]
Ritz, E. and Tomaschitz, A., Aldosterone and the kidney: a rapidly moving frontier (an update, Nephrol Dial Transplant, 29(11):2012-2019 (2013). [cited by applicant]
Azizi, Michel, et al. “Aldosterone synthase inhibition in humans”, Nephrology Dialysis Transplantation (2013); 28(1): 36-43. [cited by applicant]
Beukeaw, Danupat, et al. “Iodine-catalyzed oxidative cross-coupling of indoles and azoles: regioselective synthesis of N-linked 2-(azol-1-yl) indole derivatives”, The Journal of Organic Chemistry (2015); 8(7): 3447-3454. [cited by applicant]
Database STN, CAS Registry No. 1913832-83-3, “1H-Benzimidazole-4-carbonitrile, 2-(3-ethyl-6-methyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 19, 2016; retrieved Oct. 1… [cited by applicant]
Database STN, CAS Registry No. 1209120-48-8, “1H-Benzimidazole, 2-(3-chloro-6-methyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered Mar. 12, 2010; retrieved Oct. 14, 2022; 1 pa… [cited by applicant]
Database STN, CAS Registry No. 1355233-87-2, “3-Pyridazinecarboxylic acid, 6-chloro-5-(1-methyl-1H-benzimidazol-2-yl)-”, Chemical Abstracts Service, American Chemical Society; entered Feb. 3, 2012; retrieved Oct. 14, 20… [cited by applicant]
Database STN, CAS Registry No. 1912610-81-1, “1H-Benzimidazole-5-carbonitrile, 1-ethyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 18, 2016; retrieved Oct. 14, 2022; 1 page. [cited by applicant]
Database STN, CAS Registry No. 1912610-84-4, “1H-Benzimidazole-5-carbonitrile, 1-propyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 18, 2016; retrieved Oct. 14, 2022; 1 page. [cited by applicant]
Database STN, CAS Registry No. 1915555-78-0, “1H-Benzimidazole-5-carboxylic acid, 2-(3,6-dimethyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 22, 2016; retrieved Oct. 14… [cited by applicant]
Database STN, CAS Registry No. 1915618-52-8, “1H-Benzimidazole-5-carbonitrile, 2-(3-ethyl-6-methyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 22, 2016; retrieved Oct. 1… [cited by applicant]
Database STN, CAS Registry No. 1915618-64-2, “1H-Benzimidazole-5-carbonitrile, 1-(2-methylpropyl)-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 22, 2016; retrieved Oct. 14, 2022… [cited by applicant]
Database STN, CAS Registry No. 1917511-16-0, “1H-Benzimidazole-5-carbonitrile, 1-methyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 25, 2016; retrieved Oct. 14, 2022; 1 page. [cited by applicant]
Database STN, CAS Registry No. 1917621-66-9, “1H-Benzimidazole-6-carbonitrile, 2-(3-ethyl-6-methyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 25, 2016; retrieved Sep. 2… [cited by applicant]
Database STN, CAS Registry No. 1917959-75-1, “1H-Benzimidazole-6-carbonitrile, 1-methyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 25, 2016; retrieved Oct. 14, 2022; 1 page. [cited by applicant]
Database STN, CAS Registry No. 1918181-17-5, “1H-Benzimidazole-4-carbonitrile, 2-(3,6-dimethyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 25, 2016; retrieved Oct. 14, 2… [cited by applicant]
Database STN, CAS Registry No. 1918800-31-3, “1H-Benzimidazole-5-carbonitrile, 2-(3,6-dimethyl-4-pyridazinyl)-1-ethyl-”, Chemical Abstracts Service, American Chemical Society; entered May 26, 2016; retrieved Oct. 14, 20… [cited by applicant]
Database STN, CAS Registry No. 1919678-76-4, “1H-Benzimidazole-5-carbonitrile, 1-(1-methylethyl)-2-(4-pyridazinyl)”, Chemical Abstracts Service, American Chemical Society; entered May 27, 2016; retrieved Oct. 14, 2022; … [cited by applicant]
Database STN, CAS Registry No. 1919763-04-4, “1H-Benzimidazole-6-carbonitrile, 2-(3,6-dimethyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 27, 2016; retrieved Oct. 14, 2… [cited by applicant]
Database STN, CAS Registry No. 1920995-91-0, “1H-Benzimidazole-5-carboxylic acid, 1-methyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 30, 2016; retrieved Oct. 14, 2022; 1 pag… [cited by applicant]
Database STN, CAS Registry No. 1921020-29-2,“1H-Benzimidazole-5-carbonitrile, 1-cyclopropyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 30, 2016; retrieved Oct. 14, 2022; 1 pa… [cited by applicant]
Database STN, CAS Registry No. 1921435-96-2, “1H-Benzimidazole-1-acetic acid, 2-(3,6-dimethyl-4-pyridazinyl)”, Chemical Abstracts Service, American Chemical Society; entered May 31, 2016; retrieved Oct. 14, 2022; 1 page. [cited by applicant]
Database STN, CAS Registry No. 1921438-70-1, “1H-Benzimidazole-5-carbonitrile, 2-(3,6-dimethyl-4-pyridazinyl)-1-methyl-”, Chemical Abstracts Service, American Chemical Society; entered May 31, 2016; retrieved Oct. 14, 2… [cited by applicant]
Database STN, CAS Registry No. 1921449-39-9, “1H-Benzimidazole-6-carbonitrile, 2-(3,6-dimethyl-4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered May 31, 2016; retrieved Oct. 14, 2022; 1 pa… [cited by applicant]
Database STN, CAS Registry No. 1990187-60-4, “1H-Benzimidazole-4-carbonitrile, 1-methyl-2-(4-pyridazinyl)-”, Chemical Abstracts Service, American Chemical Society; entered Sep. 9, 2016; retrieved Oct. 14, 2022; 1 page. [cited by applicant]
Deng, Xiaohu, et al., “Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCI3”, The Journal of Organic Chemistry (2011); 76(20): 8262-8269. [cited by applicant]
European Patent Application No. 17887556.3, Office Action mailed Aug. 4, 2021; 4 pages. [cited by applicant]
Extended European Search Report, dated May 17, 2022 for European Application No. 20738530.3, 10 pages. [cited by applicant]
PubChem CID 3368479, Create Date: Sep. 7, 2005 (Sep. 7, 2005). [cited by applicant]
PubChem CID 91479648, Create Date: Mar. 17, 2015 (Mar. 17, 2015). [cited by applicant]
International Application No. PCT/US2017/068180; International Preliminary Report On Patentability mailed Jul. 11, 2019, 10 pages. [cited by applicant]
International Application No. PCT/US2017/068190; International Preliminary Report On Patentability mailed Jul. 11, 2019, 7 pages. [cited by applicant]
International Application No. PCT/US2020/012786; International Preliminary Report On Patentability mailed Jun. 16, 2021, 6 pages. [cited by applicant]
International Application No. PCT/US2020/012786; International Search Report and Written Opinion mailed May 20, 2020, 11 pages. [cited by applicant]
Rouffet, Matthieu, et al., “From sensors to silencers: Quinoline-and benzimidazole-sulfonamides as inhibitors for zinc proteases”, Journal of the American Chemical Society (2010); 132(24): 8232-8233. [cited by applicant]
Yang, Yang, et al., “Metalloprotein inhibitors for the treatment of human diseases”, Current Topics in Medicinal Chemistry (2016); 16(4): 384-396. [cited by applicant]
International Search Report and Written Opinion mailed Jun. 29, 2018 for Application No. PCT/US2017/068190. [cited by applicant]
International Search Report and Written Opinion mailed Jul. 6, 2018 for Application No. PCT/US2017/068180. [cited by applicant]
[No Author Listed], Compound Summary for CID 45792664. PubChem, NIH, U.S. National Library of Medicine, National Center for Biotechnology Information. Jun. 21, 2010. https://pubchem.ncbi.nlm.nih.gov/compound/45792664 [l… [cited by applicant]
Extended European Search Report, dated May 28, 2020 for European Application No. 17886279.3. [cited by applicant]
Extended European Search Report, dated Jul. 24, 2020 for European Application No. 17887556.3. [cited by applicant]
Hoyt et al., Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys. ACS Med Chem Lett. Apr. 7, 2015;6(5):573-8. doi: 10.1021/acsmedchemlett.5b00054. eCollection May 14, 2015. [cited by applicant]
Li et al. Novel mutations in the CYP11B2 gene causing aldosterone synthase deficiency. Mol Med Rep, Apr. 2016;13 (4): 3127-32. doi: 10.3892/mmr.2016.4906. Epub Feb. 18, 2016. [cited by applicant]
Meredith et al., “Discovery and in Vivo Evaluation of Potent Dual CY11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors,” ACS Medicinal Chemistry Letters, 2013, 4, 1203-1207. [cited by applicant]
Papillon et al., “Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects,” J. Med. Chem., 2015, … [cited by applicant]
Sajith et al., Design, synthesis and structure-activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents, European Journal of Medicinal Chemistry, 201… [cited by applicant]
Sajith et al., “Microwave enhanced Suzuki coupling: a diversity-oriented approach to the synthesis of highly functionalised 3-substituted-2-aryl/heteroaryl imidazo[4,5-b]pyridines,” Tetrahedron Letters, (2012), 53: 1036… [cited by applicant]
WebMD, “Inherited Metabolic Disorders.: Types, Causes, Symptoms and Treatments,” 2014, 5 pages, retrieved from http://www.webmd.com/a-to-z-guides/inherited-metabolic-disorder-types-and-treatments?page-2>. [cited by applicant]
Xue et al., “Cu(i) recognition via cation-π and methionine interactions in CusF,” Nature Chemical Biology, (2008) vol. 4, No. 2, 107-109. [cited by applicant]
[No Author Listed], Auto-Immune Diseases. MedlinePlus. Jul. 21, 2014. http://www.nlm.nih.gov/medlineplus/autoimmunedisease.html [last accessed Oct. 29, 2018],5 pages. [cited by applicant]
[No Author Listed], Compound Summary for CID 45792664. PubChem, NIH, U.S. National Library of Medicine, National Center for Biotechnology Information. Jun. 21, 2010. [cited by applicant]
[No Author Listed], Compound Summary for CID 71940203. PubChem, NIH, U.S. National Library of Medicine, National Center for Biotechnology Information. Nov. 29, 2013. https://pubchem.ncbi.nlm.nih.gov/compound/71940203 [l… [cited by applicant]
[No Author Listed], Definition of Cancer. MedicineNet.com. Sep. 18, 2004. http://www.medterms.com [last accessed Oct. 29, 2018], 1 page. [cited by applicant]
[No Author Listed], Infections: MedlinePlus. Jul. 6, 2016. https://medlineplus.gov/infections.html [last accessed Oct. 29, 2018], 10 pages. [cited by applicant]
[No Author Listed], Myeloproliferative disorders. University of Maryland Medical Center. Feb. 2, 2016. http://umm.edu/health/medical/altmed/condition/myeloproliferative-disorders [last accessed Oct. 29, 2018], 8 pages. [cited by applicant]
[No Author Listed], Neurological Disorders. Sep. 26, 2016. UCSF Medical Center https://www.ucsfhealth.org/conditions/neurological_disorders/ [last accessed Oct. 29, 2018], 1 page. [cited by applicant]
[No Author Listed], Search Results. Aurora Fine Chemicals. Date unknown. http://online.aurorafinechemicals.com/navigate.asp?pgNo=I [last accessed Apr. 24, 2018], 25 pages. [cited by applicant]
[No Author Listed], Search Results. ChemSpace. Date unknown. https://chem-space.com/search/5ac4e53b-7bf084-266f2302-fbfd7af?currency=usd&per_page=48&uom=g [last accessed Apr. 24, 2018], 3 pages. [cited by applicant]
Bousquet et al. Spironolactone for nonresolving central serous chorioretinopathy, The Journal of Retinal and Vitreous Diseases, 35(12) (2015). [cited by applicant]
Brown, Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis, Nat Rev Nephrol, Aug. 2013; 9(8):459-69. doi: 10.1038/nmeph.2013. 110. Epub Jun. 18, 2013. Review. [cited by applicant]
Calhoun et al. Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial, Circulation, 124: 1945-1955 (2… [cited by applicant]
Deliyanti et al. Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy. Hypertension, 2012;59:607-13. doi: 10.1161/HYPERTENSIONAHA.111.188136. Epub Jan. 23, 2012. [cited by applicant]
D'Ydew Alle et al., HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPBI-induced Charcot-Marie-Tooth disease. Nat Med. Jul. 24, 2011; 17(8):968-74. doi: 10.1038/nm.2396. [cited by applicant]
Escher, et al. High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome. Nephrol Dial Transplant. Jun. 2009;24(6):1870-5. doi: 10. 1093/ndt/gfn763. Epub Jan. 16, 2009. [cited by applicant]
Goker, et al., Synthesis and Potent Antifungal Activity Against [cited by applicant]
Haggerty et al., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci US A Apr. 15, 2003;100(8):4389-94. Epub Apr. 3, 2003. [cited by applicant]
Houlden et al., Mutations in the HSP27 (HSPBI) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology. Nov. 18, 2008;71(21):1660-8. doi: 10.1212/01.wnl.0000319696.14225.67. Epub Oct. 1, 2008. [cited by applicant]
Hoyt et al. Discovery of Benzimidazole CYP1182 Inhibitors with in Vivo Activity in Rhesus Monkeys, ACS Medicinal Chemistry Letters, 6: 573-578 (2015). [cited by applicant]
Kijima et al., Small heat shock protein 27 mutation in a Japanese patient with distal hereditary motor neuropathy. J Hum Genet. 2005;50(9):473-6. Epub Sep. 10, 2005. [cited by applicant]
Li et al. Novel mutations in the CYP11B2 gene causing aldosterone synthase deficiency. Mol Med Rep, Apr. 2016;I3 (4): 3127-32. doi: 10.3892/mmr.2016.4906. Epub Feb. 18, 2016. [cited by applicant]
Li et al., “CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis”, World J Gastroenterol. (2000); 6(6): 885-7. [cited by applicant]
Machine Translation for Shen et al. CN 103625783 (Year: 2014). [cited by applicant]
Meredith, E.L. et al.,. Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors, ACS Medicinal Chemistry Letters, 4(12): 1203-1207 (2013). [cited by applicant]
Milokhov et al., “Reaction of 2-Hetaryl-2-(tetrahydro-2-furanyliden)acetonitriles with 1,3-N, N Binucleophiles,” Synlett, 2012, 23:2063-2068. [cited by applicant]
Namsolleck et al. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrology Dialysis Transplantation, Feb. 2014; 29(1):i62-i68. Aldosterone synthase inhibitors in cardiovascular and renal diseases… [cited by applicant]
Noguchi et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats, International Journal of Molecular Medicine, 26(3):407-13 (2010). [cited by applicant]
Pacurari et al., The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360. doi: 10.1155/2014/689360. Epub Apr. 6, 2014. Review. [cited by applicant]
Pindur et al., “Cyclization reactions of 2,2′-bis-N-methylindolyl to potential protein kinase C inhibitors”, Heterocycles, 1994, vol. 38, No. 10, pp. 2267-2276. [cited by applicant]
Sajith et al., Design, synthesis and structure—activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents. Eur J Med Chem. Jan. 7, 2015;89:21-31. doi: … [cited by applicant]
Sajith et al., “Microwave enhanced Suzuki coupling: a diversity-oriented approach to the synthesis o highly functionalised 3-substituted-2-aryl/heteroaryl imidazo[4,5-b ]pyridines,” Tetrahedron Letters, (2012), 53: 1036… [cited by applicant]
Savitha et al., “Palladium-Catalyzed Suzuki Cross-Coupling of 2-HaloDeazapurines with Potassium Organotrifluoroborate Salts in the Regioselective Synthesis of Imidazo[4,5-b]pyridine Analogues,” Aust. J. Chem. 2016, 69, … [cited by applicant]
Supuran, Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. Feb. 2008;7(2): 168-81. doi: 10.1038/nrd2467. Review. [cited by applicant]
WebMD. Inherited Metabolic Disorders.: Types, Causes, Symptoms and Treatments. (2014). Web: <http://www.webmd.com/ a-to-z-guides/inherited-metabolic-disorder-types-and-treatments?page=2>. (Year: 2014). [cited by applicant]
Xue et al., “Cu(i) recognition via cation-TT and methionine interactions in CusF,” Nature Chemical Biology, (2008) vol. 4, No. 2, 107-109. [cited by applicant]
Cited By (1)
US 12,553,840